Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...
Turquoise Hill Resources TRQ -31% after Rio Tinto's Mongolia project expected to be delayed. More news on: China Lending Corporation, Adamis Pharmaceuticals Corporation, Workhorse Group Inc., Stocks on the move, Read more ...
On July 9 th , Sandoz, a division of Novartis ( NVS ), announced the long-awaited US retail launch of SYMJEPI in both adult and pediatric doses. SYMJEPI is single-dose, pre-filled syringe drug/device combination for emergency treatment of Type 1 allergic reactions, including anaphylaxis th...
Mylan N.V. ( MYL -5.2% ) slips on below-average volume on the heels of a Bloomberg report that patients and pharmacists are still scrambling to obtain emergency allergic reaction treatment EPiPen (epinephrine injection), in short supply for over a year now. More news on: Mylan N.V., Ad...
Acacia Communications (NASDAQ: ACIA ) +37% on being acquired by Cisco. More news on: Acacia Communications, Inc., Camber Energy, Inc., Check-Cap Ltd., Stocks on the move, Read more ...
SAN DIEGO, July 09, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) provided an update that Sandoz Inc. (Sandoz), a Novartis division, today announced the U.S. retail launch of SYMJEPI™ (epinephrine) 0.3 mg and 0.15 mg Injections, making both the adult...
Introduction Adamis Pharmaceuticals ( ADMP ) is a generic drug manufacturer which recently launched an off-patent version of Mylan's ( MYL ) Epipen (Symjepi). Despite the hype surrounding the nature of this drug, Sjympei took over 3 times the period it normally takes for a generic drug to ...
SAN DIEGO, June 27, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the litigation with kaléo Inc. regarding kaléo’s claims of patent infringement relating to Adamis’ higher dose naloxone injection product (...
Adamis Pharmaceuticals ( ADMP ) is a specialty biopharmaceutical company dedicated to developing and commercializing various therapeutic products. The company's leading product, SYMJEPI, is a pre-filled syringe "PFS" device holding 0.3mg or 0.15mg dosage of epinephrine that has FDA approval fo...
Based on FDA feedback, Adamis Pharmaceuticals ( ADMP -4.5% ) has removed kaléo's EVZIO (naloxone HCl injection) 2 mg auto-injector as the Reference Listed Drug (RLD) in its marketing application seeking approval for its higher dose naloxone injection product for the emergency trea...
News, Short Squeeze, Breakout and More Instantly...
Adamis Pharmaceuticals Corporation Company Name:
ADMP Stock Symbol:
NASDAQ Market:
Adamis Pharmaceuticals Corporation Website:
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing sm...
SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. Q2 2023 ...
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in...